Oryzon Genomics SA
MAD:ORY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Oryzon Genomics SA
MAD:ORY
|
ES |
|
D
|
DTE Energy Co
XMUN:DGY
|
US |
|
C
|
Cloudflare Inc
DUS:8CF
|
US |
|
K
|
Keyrus SA
F:5UP
|
FR |
|
S
|
Starr Peak Mining Ltd
XTSX:STE
|
CA |
|
Thungela Resources Ltd
F:6UP
|
ZA |
|
K
|
Kingdee International Software Group Co Ltd
XMUN:KDIC
|
CN |
Intrinsic Value
Is ORY undervalued or overvalued?
See the intrinsic value estimate for Oryzon Genomics SA and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
ORY looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with ORY’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Oryzon Genomics Does
Oryzon Genomics is a drug development company focused on medicines that change how genes are switched on and off. Its main work is discovering and testing epigenetic drugs, especially compounds that block LSD1, an enzyme involved in cancer and some brain disorders. The company does not sell everyday consumer products; it builds drug candidates that may eventually be licensed or sold as prescription medicines if they win approval.
- Headquarters
- Spain ES
- Employees
- 46
- IPO date
- Dec 10, 2015
Earnings Waterfall
Oryzon Genomics SA
The intrinsic value for Oryzon Genomics SA (ORY) under the Base Case is hidden EUR.
Compared with the current market price of 2.53 EUR, the stock appears hidden.